Companies

Light at the end of the tunnel for Dr Reddy’s Laboratories

Dhuraivel Gunasekaran BL Research Bureau | Updated on January 11, 2018 Published on May 16, 2017

drl_2948033f

The shares of Dr Reddy’s Laboratories rebounded over the last two sessions after it touched its 52-week low last Friday, post-announcement of its fourth-quarter results.

There is renewed interest in the stock from the investor fraternity, in the belief that the ongoing regulatory issues have been factored into the share price, creating a buying opportunity for the medium term.

Last Friday, following the declaration of its Q4 results, the stock corrected to its lowest level in the last one year, shedding over 42 per cent from its peak seen in late July 2016. On Monday, the stock gained more than 3 per cent. Consecutively, the share price rose about 2 per cent in early trade on Tuesday.

The correction in the share prices can be attributed to regulatory inspections of its three facilities by the USFDA. The company received USFDA warning letters regarding deviations from current good manufacturing practices (cGMP) at its active pharmaceutical ingredients (APIs) plants at Srikakulam and Miryalaguda and for violations at its oncology formulation facility at Duvvada. These led to a disruption in supplies, delays in approvals and remedial costs. All this, in turn, impacted the revenue of the company badly.

The USFDA, however, completed its re-inspection of these facilities during March and April 2017 and issued a Form 483 with 11 observations. The issue of Form 483 implies that the USFDA has found minor deviations in manufacturing practices that need to be addressed. The remediation measures with respect to these key facilities is important for the company as they continue to weigh on the overall performance.

Q4 results

Dr Reddy’s Lab reported a 175 per cent growth in consolidated net profit to Rs 337.6 crore in the March quarter as against Rs 122.6 crore seen in the same period last year. The nearly three-fold jump in the bottom line was attributable to the low base in the corresponding quarter of Q4FY16, which was impacted due to the writing down of receivables worth Rs 400 crore from Venezuela.

Its consolidated net sales fell by around 5 per cent to Rs 3,498.5 crore from Rs 3,695 crore of the period in the last year due to lower North American sales.

For the full year FY 17, consolidated net sales were at Rs 13,866 crore, down 9 per cent year-on-year, while the consolidated net profit stood at Rs 1,292 crore, down 39 per cent over the last year.

Dr Reddy’s has a vertically integrated business model with three segments — global generics, pharmaceuticals services and active ingredients, and proprietary products. Around 82 per cent of its revenue is currently derived from global generics.

Muted US performance

The revenue from North America fell by 19 per cent in the fourth-quarter to Rs 1,535 crore as compared to the same quarter in the previous year, due to pricing pressure and increased competition in some generics such as Valgancyclovir. Lack of new launches due to regulatory clamp-down also impacted the revenue. The company’s North America business has accounted for 43 per cent of the overall revenue. As on March 2017, cumulatively, the company has 101 filings pending (99 ANDAs, 2 NDAs), of which 62 are Para IV opportunities and 21 FTFs. During the earning call, the management guided for about 10-plus launches in FY18.

Scale-up across Europe and EM

Gradual sequential improvement is seen in the revenue from emerging markets on account of the appreciation in the Russian Ruble and improving macros across geographies. The revenue from Russia for the fourth quarter grew by 26 per cent YoY to Rs 340 crore. Commercialisation of biosimilars across emerging markets has also seen meaningful traction. The European business reported strong growth on a YoY basis on the back of new launches.

The revenue from India rose by 8 per cent YoY at Rs 571 crore during the fourth quarter. This was impacted by demonetisation and the effect of price controls.

The Pharmaceutical Services and Active Ingredients (PSAI) business, which accounts for 15 per cent of the company’s revenue, declined around 6 per cent YoY during the quarter.

Operating profit was at Rs 630 crore. The EBITDA margin for the quarter stood at 18 per cent, a sequential decline of 24 per cent from the December quarter.

Published on May 16, 2017

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Sincerely,

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.